Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Breakthrough Hemolysis in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Ravulizumab: Results of a 52-Week Extension from Two Phase 3 Studies

Anita Hill, MD PhD, Caroline I. Piatek, Régis Peffault de Latour, MD PhD, Lily LL Wong, MD FRCPath, Richard A. Wells, MD DPhil, Robert A. Brodsky, MD, Jin Seok Kim, MD PhD, Junichi Nishimura, MD PhD, Philip Kuriakose, MD, Rodrigo Pavani, Peng Liu, Stephan Ortiz, RPh, PhD, Hubert Schrezenmeier, MD, Jong-Wook Lee, MD PhD, Austin Kulasekararaj, MDMBBS,MRCP,FRCPath

Blood (2019) 134 (Supplement_1): 952.

https://doi.org/10.1182/blood-2019-128929

Published: 2019

Journal Articles

Long Term Nomacopan Administration Results in Complete Transfusion Independence in Previously Transfusion-Dependent PNH Patients

Austin Kulasekararaj, MBBS MDMRCP FRCPath, Wynne Weston-Davies, Tadeusz Robak, MD, Miles Nunn, PhD, Agnieszka Piekarska, MD, Anna Szmigielska-Kaplon, MD, Anita Hill, MD PhD

Blood (2019) 134 (Supplement_1): 4797.

https://doi.org/10.1182/blood-2019-125263

Published: 2019

Journal Articles

Predictors of Response to Erythropoietin in Autoimmune Hemolytic Anemia

Bruno Fattizzo, MD, Marc Michel, Laetitia Languille, Juri Giannotta, MD, Henrik Frederiksen, MD Prof, Francesca Romana Mauro, MD, Bernd Jilma, Elisa Lucchini, MD, Andrea Patriarca, MD, Francesco Zaja, MD, Anita Hill, MD PhD, Sigbjorn Berentsen, MD PhD, Wilma Barcellini

Blood (2019) 134 (Supplement_1): 3516.

https://doi.org/10.1182/blood-2019-125524

Published: 2019

Journal Articles

Subcutaneous Alemtuzumab Has Activity in Treatment-Naïve Patients with Acquired Aplastic Anemia

Ana Rita Da Fonseca, MD, Anita Hill, MD PhD, Patricia Eiko Yamakawa, MD, Iara Baldim Rabelo, MD PhD, Andre Domingues Pereira, MD, Vinicius Campos de Molla, MD, Matheus Vescovi Gonçalves, MD PhD, Morag Griffin, MD, Talha Munir, MD, Peter Hillmen, MD PhD, Louise Arnold, MD, Kathryn Riley, MD, Antonio M. Risitano, MD PhD, Phillip Scheinberg, MD, Celso Arrais-Rodrigues, MD PhD

Blood (2019) 134 (Supplement_1): 2503.

https://doi.org/10.1182/blood-2019-130719

Published: 2019

Journal Articles

One-Year Efficacy and Safety from a Phase 3 Trial of Ravulizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Receiving Prior Eculizumab Treatment

Austin Kulasekararaj, MDMBBS,MRCP,FRCPath, Anita Hill, MD PhD, Saskia Langemeijer, MD PhD, Richard A. Wells, MD DPhil, F. Ataulfo Gonzalez-Fernandez, Anna Gaya, Emilio Ojeda Gutierrez, Caroline I. Piatek, Lindsay D Mitchell, MBChB, MRCP(UK), FRCPath, Kensuke Usuki, Alberto Bosi, Robert A. Brodsky, MD, Masayo Ogawa, MD FAAP, Ji Yu, Stephan Ortiz, RPh, PhD, Alexander Röth, MD PhD, Jong-Wook Lee, MD PhD, Régis Peffault de Latour, MD PhD

Blood (2019) 134 (Supplement_1): 2231.

https://doi.org/10.1182/blood-2019-128746

Published: 2019

Journal Articles

A Prospective Analysis of Breakthrough Hemolysis in 2 Phase 3 Randomized Studies of Ravulizumab (ALXN1210) Versus Eculizumab in Adults with Paroxysmal Nocturnal Hemoglobinuria

Robert A. Brodsky, MD, Regis Peffault De Latour, Scott T. Rottinghaus, MD, Alexander Röth, MD, Antonio M. Risitano, MD PhD, Ilene C. Weitz, MD, Peter Hillmen, MB ChB, PhD FRCP, FRCPath, Jaroslaw P. Maciejewski, Jeffrey Szer, MBBS, Jong-Wook Lee, MD PhD, Austin G. Kulasekararaj, MBBS, MD MRCP, FRCPath, Lori Volles, MD, Andrew I. Damokosh, PhD, Stephan Ortiz, RPh, PhD, Lori Shafner, PhD, Anita Hill, MD PhS, Hubert Schrezenmeier, MD

Blood (2018) 132 (Supplement 1): 2330.

https://doi.org/10.1182/blood-2018-99-110874

Published: 2018

Journal Articles

Results from a Phase 3, Multicenter, Non-Inferiority Study of Ravulizumab (ALXN1210) Versus Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Currently Treated with Eculizumab

Austin G. Kulasekararaj, MBBS, MD MRCP, FRCPath, Anita Hill, MD PhS, Scott T. Rottinghaus, MD, Saskia Langemeijer, MD PhD, Richard A. Wells, MD DPhil, F. Ataulfo Gonzalez-Fernandez, Anna Gaya, Jong-Wook Lee, MD PhD, Emilio Ojeda Gutierrez, Caroline I. Piatek, Jeffrey Szer, MBBS, Antonio M. Risitano, MD PhD, Shinji Nakao, MD PhD, Eric Bachman, Lori Shafner, PhD, Andrew I. Damokosh, PhD, Stephan Ortiz, RPh, PhD, Alexander Röth, MD, Regis Peffault De Latour

Blood (2018) 132 (Supplement 1): 625.

https://doi.org/10.1182/blood-2018-99-119147

Published: 2018

Journal Articles

Successful Pregnancy Outcomes in Paroxysmal Nocturnal Hemoglobinuria with Long-Term Eculizumab Treatment

Richard Kelly, MD, Louise Arnold, BSc, MA, Stephen J. Richards, PhD, Anita Hill, MD, Charlotte Bomken, MD, John Hanley, MD, Andrew Loughney, MD, PhD, Gus Khursigara, PhD, Russell P. Rother, PhD, Elizabeth Chalmers, MD, Edward Fitzsimons, MD, Ryotaro Nakamura, MD, Anna Gaya, MD, Bruno Rotoli, MD, Antonio M. Risitano, MD, PhD, Joerg Schubert, MD, Peter Hillmen, MB, PhD

Blood (2008) 112 (11): 4576.

https://doi.org/10.1182/blood.V112.11.4576.4576

Published: 2008

Journal Articles

Modification of the Eculizumab Dose to Successfully Manage Intravascular Breakthrough Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria.

Richard Kelly, MD, Louise Arnold, BSc, MA, Stephen Richards, PhD, Anita Hill, MD, Sandra vanBijnen, MD, Petra Muus, MD, PhD, Donna Dorr, RN, MSN, AOCN, Robert Brodsky, MD, Gus Khursigara, PhD, Russell P. Rother, PhD, Peter Hillmen, MBChB, PhD

Blood (2008) 112 (11): 3441.

https://doi.org/10.1182/blood.V112.11.3441.3441

Published: 2008

Journal Articles

Eculizumab Reduces Pulmonary Hypertension through Inhibition of Hemolysis-Associated Nitric Oxide Consumption in Patients with Paroxysmal Nocturnal Hemoglobinuria

Anita Hill, MD, Russell P. Rother, PhD, Xunde Wang, MD, Robert J Sapsford, MD, Paul O Collinson, MD, David C Gaze, PhD, Sidney M Morris, Jr., PhD, Andrew Scally, Kerry Quinn-Senger, PhD, Stephen J Richards, PhD, Monica Bessler, MD, PhD, Richard Kelly, MD, Peter Hillmen, MBChB, PhD, Mark Gladwin, MD

Blood (2008) 112 (11): 486.

https://doi.org/10.1182/blood.V112.11.486.486

Published: 2008

Journal Articles

A High Purity Factor VIII/vWF Complex Concentrate Is Effective in the Management of Mild Hemophillia A with Inhibitors: A Case Report.

Srivasavi Dukka, MBBS, MD, MRCP, Susan Kaye, RGN,CNS, John Ashcroft, PhD, Anita Hill, MD, Liakat A. Parapia, FRCP,FRCPE,FRC Path

Blood (2007) 110 (11): 3959.

https://doi.org/10.1182/blood.V110.11.3959.3959

Published: 2007

Journal Articles

Survival of Patients with Hematological Malignancy Admitted to the Intensive Care Unit (ICU): Prognostic Factors and Outcome Compared to Unselected Medical ICU Admissions.

Quentin A. Hill, MD, Anita Hill, MD, Richard Kelly, MD, Chetan Patalappa, MD, Annika M. Whittle, MD, Andrew J. Scally, MSc, Anthony Hughes, MD, John Ashcroft, MD, PhD

Blood (2006) 108 (11): 3319.

https://doi.org/10.1182/blood.V108.11.3319.3319

Published: 2006

Journal Articles

High Definition Contrast-Enhanced MR Imaging in Paroxysmal Nocturnal Hemoglobinuria (PNH) Suggests a High Frequency of Subclinical Thrombosis.

Anita Hill, MD, Scott A. Reid, PhD, Russell P. Rother, PhD, Mark T. Gladwin, MD, Paul O. Collinson, PhD, David C. Gaze, PhD, Angela Lowe, DCR, Ashley Guthrie, FRCR, Mohan U. Sivananthan, MD, Peter Hillmen, PhD

Blood (2006) 108 (11): 979.

https://doi.org/10.1182/blood.V108.11.979.979

Published: 2006

Journal Articles

The Incidence and Prevalence of Paroxysmal Nocturnal Hemoglobinuria (PNH) and Survival of Patients in Yorkshire.

Anita Hill, MD, Philip J. Platts, MRes, Alex Smith, PhD, Stephen J. Richards, PhD, Matthew J. Cullen, MSc, Quentin A. Hill, MD, Eve Roman, PhD, Peter Hillmen, PhD

Blood (2006) 108 (11): 985.

https://doi.org/10.1182/blood.V108.11.985.985

Published: 2006

Journal Articles

Blockade of Intravascular Hemolysis in PNH with the Terminal Complement Inhibitor Eculizumab Unmasks Low-Level Hemolysis Potentially Occurring through C3 Opsonization.

Anita Hill, MD, Russell P. Rother, PhD, Antonio M. Risitano, PhD, Duncan S. Cole, PhD, Matthew J. Cullen, MSc, Stephen J. Richards, PhD, Carmine Selleri, MD, Patrizia Ricci, BSc, Bruno Rotoli, MD, Lucio Luzzatto, PhD, Peter Hillmen, PhD

Blood (2006) 108 (11): 972.

https://doi.org/10.1182/blood.V108.11.972.972

Published: 2006

Journal Articles

Nitric Oxide Consumption and Pulmonary Hypertension in Patients with Paroxysmal Nocturnal Hemoglobinuria.

Anita Hill, MD, Xunde Wang, PhD, Robert J. Sapsford, MD, Rother P. Russell, PhD, Alison L. Farrell, PGDip, Hilary A. Jessop, Gina M. McGawley, MSc, David L. Oxborough, BHSc, Paul Pleasants, BSc, Stephen J. Richards, PhD, Louise M. Arnold, BSc, David M. Buchanan, MA, Sara Rollinson, PhD, Mark T. Gladwin, MD, Peter Hillmen, PhD

Blood (2005) 106 (11): 1046.

https://doi.org/10.1182/blood.V106.11.1046.1046

Published: 2005

Journal Articles

The Effect of Eculizumab Therapy on Red Cell Response Kinetics in Patients with Paroxysmal Nocturnal Hemoglobinuria.

Stephen J. Richards, PhD, Matthew J. Cullen, MSc, Anita J. Dickinson, MSc, Anita Hill, MD, David Buchanon, MA, Louise Arnold, BSc, Modupe Elebute, MD, Russell P. Rother, PhD, Peter Hillmen, PhD

Blood (2005) 106 (11): 1047.

https://doi.org/10.1182/blood.V106.11.1047.1047

Published: 2005

Journal Articles

Sustained Control of Hemolysis and Symptoms and Reduced Transfusion Requirements over a Period of 2 Years in Paroxysmal Nocturnal Hemoglobinuria (PNH) with Eculizumab Therapy.

Anita Hill, MD, Dupe Elebute, MD, Judith C. Marsh, MD, Stephen J. Richards, PhD, Bruce McNutt, MD, Beth E. Petro, BS, Russell P. Rother, PhD, Peter Hillmen, PhD

Blood (2004) 104 (11): 2823.

https://doi.org/10.1182/blood.V104.11.2823.2823

Published: 2004

Journal Articles

Evolution of GPI-Deficient Clones Predicts Clinical Course in Paroxysmal Nocturnal Haemoglobinuria.

Stephen J. Richards, PhD, Matthew J. Cullen, MSc, Anita J. Dickinson, MSc, Claire Hall, MD, Anita Hill, MD, Peter Hillmen, PhD

Blood (2004) 104 (11): 172.

https://doi.org/10.1182/blood.V104.11.172.172

Published: 2004

NARROW

Breakthrough Hemolysis in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Ravulizumab: Results of a 52-Week Extension from Two Phase 3 Studies

Long Term Nomacopan Administration Results in Complete Transfusion Independence in Previously Transfusion-Dependent PNH Patients

Predictors of Response to Erythropoietin in Autoimmune Hemolytic Anemia

Subcutaneous Alemtuzumab Has Activity in Treatment-Naïve Patients with Acquired Aplastic Anemia

One-Year Efficacy and Safety from a Phase 3 Trial of Ravulizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Receiving Prior Eculizumab Treatment

A Prospective Analysis of Breakthrough Hemolysis in 2 Phase 3 Randomized Studies of Ravulizumab (ALXN1210) Versus Eculizumab in Adults with Paroxysmal Nocturnal Hemoglobinuria

Results from a Phase 3, Multicenter, Non-Inferiority Study of Ravulizumab (ALXN1210) Versus Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Currently Treated with Eculizumab

Successful Pregnancy Outcomes in Paroxysmal Nocturnal Hemoglobinuria with Long-Term Eculizumab Treatment

Modification of the Eculizumab Dose to Successfully Manage Intravascular Breakthrough Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria.

Eculizumab Reduces Pulmonary Hypertension through Inhibition of Hemolysis-Associated Nitric Oxide Consumption in Patients with Paroxysmal Nocturnal Hemoglobinuria

A High Purity Factor VIII/vWF Complex Concentrate Is Effective in the Management of Mild Hemophillia A with Inhibitors: A Case Report.

Survival of Patients with Hematological Malignancy Admitted to the Intensive Care Unit (ICU): Prognostic Factors and Outcome Compared to Unselected Medical ICU Admissions.

High Definition Contrast-Enhanced MR Imaging in Paroxysmal Nocturnal Hemoglobinuria (PNH) Suggests a High Frequency of Subclinical Thrombosis.

The Incidence and Prevalence of Paroxysmal Nocturnal Hemoglobinuria (PNH) and Survival of Patients in Yorkshire.

Blockade of Intravascular Hemolysis in PNH with the Terminal Complement Inhibitor Eculizumab Unmasks Low-Level Hemolysis Potentially Occurring through C3 Opsonization.

Nitric Oxide Consumption and Pulmonary Hypertension in Patients with Paroxysmal Nocturnal Hemoglobinuria.

The Effect of Eculizumab Therapy on Red Cell Response Kinetics in Patients with Paroxysmal Nocturnal Hemoglobinuria.

Sustained Control of Hemolysis and Symptoms and Reduced Transfusion Requirements over a Period of 2 Years in Paroxysmal Nocturnal Hemoglobinuria (PNH) with Eculizumab Therapy.

Evolution of GPI-Deficient Clones Predicts Clinical Course in Paroxysmal Nocturnal Haemoglobinuria.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only